Mechanisms of Osteoblastic Bone Metastasis in Prostate Cancer: Role of Prostatic Acid Phosphatase

Abstract Prostate cancer (PCa) preferentially metastasizes to bone, leading to complications including severe pain, fractures, spinal cord compression, bone marrow suppression, and a mortality of ∼70%. In spite of recent advances in chemo-, hormonal, and radiation therapies, bone-metastatic, castrate-resistant PCa is incurable. PCa is somewhat unique among the solid tumors in its tendency to produce osteoblastic lesions composed of hypermineralized bone with multiple layers of poorly organized type I collagen fibrils that have reduced mechanical strength. Many of the signaling pathways that control normal bone homeostasis are at play in pathologic PCa bone metastases, including the receptor activator of nuclear factor-κB/receptor activator of nuclear factor-κB ligand/osteoprotegerin system. A number of PCa-derived soluble factors have been shown to induce the dysfunctional osteoblastic phenotype. However, therapies directed at these osteoblastic-stimulating proteins have yielded disappointing clinical results to date. One of the soluble factors expressed by PCa cells, particularly in bone metastases, is prostatic acid phosphatase (PAP). Human PAP is a prostate epithelium-specific secretory protein that was the first tumor marker ever described. Biologically, PAP exhibits both phosphatase activity and ecto-5′-nucleotidase activity, generating extracellular phosphate and adenosine as the final products. Accumulating evidence indicates that PAP plays a causal role in the osteoblastic phenotype and aberrant bone mineralization seen in bone-metastatic, castrate-resistant PCa. Targeting PAP may represent a therapeutic approach to improve morbidity and mortality from PCa osteoblastic bone metastases.

[1]  M. Murshed Mechanism of Bone Mineralization. , 2018, Cold Spring Harbor perspectives in medicine.

[2]  A. Villers,et al.  TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. , 2018, Cancer letters.

[3]  Y. Tabata,et al.  Coupling of bone resorption and formation by RANKL reverse signalling , 2018, Nature.

[4]  H. Leong,et al.  Translational models of prostate cancer bone metastasis , 2018, Nature Reviews Urology.

[5]  U. Lerner,et al.  Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone , 2017, Clinical & Experimental Metastasis.

[6]  S. Izadmehr,et al.  Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases. , 2016, Endocrinology.

[7]  César L. Araujo,et al.  Transmembrane prostatic acid phosphatase (TMPAP) delays cells in G1 phase of the cell cycle , 2016, The Prostate.

[8]  V. Labas,et al.  Quantitative proteomics provides new insights into chicken eggshell matrix protein functions during the primary events of mineralisation and the active calcification phase. , 2015, Journal of proteomics.

[9]  C. Thoma Prostate cancer: Targeting the FGFR curbs bone metastasis , 2014, Nature Reviews Urology.

[10]  R. Randall A Promise to Our Patients with Metastatic Bone Disease , 2014, Annals of surgical oncology.

[11]  T. Rosol,et al.  Review of Animal Models of Prostate Cancer Bone Metastasis , 2014 .

[12]  P. Nelson,et al.  Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment , 2014, Clinical & Experimental Metastasis.

[13]  M. Bernards,et al.  Mineralization induction effects of osteopontin, bone sialoprotein, and dentin phosphoprotein on a biomimetic collagen substrate. , 2013, Journal of biomedical materials research. Part A.

[14]  B. Cronstein,et al.  Adenosine and bone metabolism , 2013, Trends in Endocrinology & Metabolism.

[15]  B. Evans,et al.  An emerging role for adenosine and its receptors in bone homeostasis , 2012, Front. Endocrin..

[16]  G. Manning,et al.  The Raine Syndrome Protein FAM20C Is a Golgi Kinase That Phosphorylates Bio-Mineralization Proteins , 2012, PloS one.

[17]  T. Guise,et al.  The role of TGF-β in bone metastasis: novel therapeutic perspectives. , 2012, BoneKEy reports.

[18]  Lisa N Kinch,et al.  Secreted Kinase Phosphorylates Extracellular Proteins That Regulate Biomineralization , 2012, Science.

[19]  N. Sträter,et al.  Cellular function and molecular structure of ecto-nucleotidases , 2012, Purinergic Signalling.

[20]  K. Ravid,et al.  A2B Adenosine Receptor Promotes Mesenchymal Stem Cell Differentiation to Osteoblasts and Bone Formation in Vivo* , 2012, The Journal of Biological Chemistry.

[21]  A. Leiter,et al.  Prostatic acid phosphatase is expressed in human prostate cancer bone metastases and promotes osteoblast differentiation , 2011, Annals of the New York Academy of Sciences.

[22]  J. Waxman,et al.  Bone metastasis in prostate cancer: emerging therapeutic strategies , 2011, Nature Reviews Clinical Oncology.

[23]  J. Waxman,et al.  Bone metastasis in prostate cancer: emerging therapeutic strategies , 2011, Nature Reviews Clinical Oncology.

[24]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[25]  C. Nieder,et al.  Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases , 2010, BMC Cancer.

[26]  Yaping Tu,et al.  Human Prostatic Acid Phosphatase, an Authentic Tyrosine Phosphatase, Dephosphorylates ErbB-2 and Regulates Prostate Cancer Cell Growth* , 2010, The Journal of Biological Chemistry.

[27]  B. Fredholm,et al.  Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. , 2010, Arthritis and rheumatism.

[28]  D. Waddington,et al.  New hypotheses on the function of the avian shell gland derived from microarray analysis comparing tissue from juvenile and sexually mature hens. , 2009, General and comparative endocrinology.

[29]  H. Zimmermann Prostatic acid phosphatase, a neglected ectonucleotidase , 2009, Purinergic Signalling.

[30]  B. Clarke,et al.  Normal bone anatomy and physiology. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[31]  W. Fu,et al.  Osteoblasts‐derived BMP‐2 enhances the motility of prostate cancer cells via activation of integrins , 2008, The Prostate.

[32]  Kent Wallner,et al.  Reviving the acid phosphatase test for prostate cancer. , 2007, Oncology.

[33]  A. Levine,et al.  Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. , 2007, Cancer research.

[34]  J. Chirgwin,et al.  Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases , 2006, Clinical Cancer Research.

[35]  S. Berry,et al.  The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. , 2006, The Canadian journal of urology.

[36]  O. MacDougald,et al.  Role of wnts in prostate cancer bone metastases , 2006, Journal of cellular biochemistry.

[37]  J. Nelson,et al.  The endothelin axis: emerging role in cancer , 2003, Nature Reviews Cancer.

[38]  C. Huggins,et al.  Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[39]  E. Luchter-Wasylewska Cooperative kinetics of human prostatic acid phosphatase. , 2001, Biochimica et biophysica acta.

[40]  A. Mizokami,et al.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.

[41]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[42]  L. Chung,et al.  LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis , 2000, The Prostate.

[43]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[44]  L. Lebioda,et al.  Crystal structure of human prostatic acid phosphatase , 2000, The Prostate.

[45]  C. Kao,et al.  Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate‐specific antigen‐producing tumors in athymic and SCID/bg mice using LNCaP and lineage‐derived metastatic sublines , 1998, International journal of cancer.

[46]  M. Mazumdar,et al.  Acid phosphatase: defining a role in androgen-independent prostate cancer. , 1996, Urology.

[47]  J. Puzas,et al.  Human prostatic acid phosphatase directly stimulates collagen synthesis and alkaline phosphatase content of isolated bone cells. , 1991, The Journal of clinical endocrinology and metabolism.

[48]  A. Bilska,et al.  Is the subunit of prostatic phosphatase active? Reversible denaturation of prostatic acid phosphatase. , 1990, Biochemistry international.

[49]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[50]  D. Paulson,et al.  Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.

[51]  H. Abrams Skeletal metastases in carcinoma. , 1950, Radiology.

[52]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[53]  E. Sproul,et al.  Significance of Increased Phosphatase Activity of Bone at the Site of Osteoplastic Metastases Secondary to Carcinoma of the Prostate Gland , 1936 .

[54]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[55]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[56]  S. Sheng The Urokinase-type Plasminogen Activator System in Prostate Cancer Metastasis , 2004, Cancer and Metastasis Reviews.

[57]  J. Chernoff,et al.  A phosphotyrosyl-protein phosphatase activity associated with acid phosphatase from human prostate gland. , 1984, European journal of biochemistry.

[58]  S. Arya,et al.  The LNCaP cell line--a new model for studies on human prostatic carcinoma. , 1980, Progress in clinical and biological research.